Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Stock Information for Intellicheck Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Intellicheck Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.